Targets › GSR
1 program from 1 company in 8 trials: 5 Phase 2, 3 Phase 1; Neurology, Oncology; next expected readout Dec 2028.
Catalyzes the reduction of glutathione disulfide (GSSG) to reduced glutathione (GSH). Constitutes the major mechanism to maintain a high GSH:GSSG ratio in the cytosol. (UniProt, P00390)
Open in Phaseline: the race on GSR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| General Oncology | Carmustine Glutathione reductase inhibitor | GSR | Phase 1 | Pancreatic Adenocarcinoma Metastatic; Metastatic Malignant Neoplasm in the Liver; Glioblastoma Multiforme; Non-Hodgkin Lymphoma … | Dec 2028 |
Glioblastoma Multiforme (2) Pancreatic Adenocarcinoma Metastatic (1) Metastatic Malignant Neoplasm in the Liver (1) Non-Hodgkin Lymphoma (1) Brain Tumor - Metastatic (1) Autoimmune Disease (1) Metastatic Uveal Melanoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.